ClinicalTrials.gg
CompletedNCT01767116PEARL-IIIUpdated Jul 12, 2021Results posted

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin in Chronic Hepatitis C Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.

Enrollment
27th of 174
419 · median 107
Started
2012
with 17 others
Phase 3
61 of 175
none open now
Registered
134th of 175
by date
Lead sponsor
4 of 175
AbbVie (prior sponsor, Abbott)

Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 27th largest by enrollment of the 174 interventional ones that give a count, is one of 18 that started in 2012, is one of 61 in phase 3, and was the 134th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 175 studies testing ribavirin in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without cirrhosis.

Read the detailed description

A randomized, double-blind, multicenter study to evaluate the safety and antiviral activity of the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with and without ribavirin (RBV) in treatment-naïve, noncirrhotic participants with chronic hepatitis C virus genotype 1b (HCV GT1b) infection.

03

Conditions studied

  • Chronic Hepatitis C Infection

Keywords

  • Interferon-Free
  • Hepatitis C Genotype 1b
  • Chronic Hepatitis C
  • Hepatitis C Virus
  • Hepatitis C
  • Treatment-Naive
  • Paritaprevir
  • Ombitasvir
  • Dasabuvir
  • Viekira PAK
  • Ribavirin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be practicing specific forms of on study treatment, or be for more than 2 years or surgically sterile
  • Chronic , genotype 1b-infection (HCV RNA level greater than or equal to 10,000 IU/mL at screening)
  • Subject has never received antiviral treatment for hepatitis C infection
  • No evidence of liver cirrhosis

Exclusion criteria

Exclusion Criteria:

  • Significant liver disease with any cause other than as the primary cause
  • Positive surface antigen or anti- antibody
  • Positive screen for drugs or alcohol
  • Significant sensitivity to any drug
  • Use of medications within 2 weeks of dosing
  • Abnormal laboratory tests
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
419 participants (actual)

Study arms

  • Experimental
    ABT-450/r/ABT-267 and ABT-333, Plus RBV

    ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin

  • Experimental
    ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV

    ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Placebo for ribavirin

Interventions

  • DrugABT-450/r/ABT-267, ABT-333

    Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir

    Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

    Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK

  • Capsule

  • DrugPlacebo for ribavirin

    Capsule

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL. The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b infection treated with telaprevir and peginterferon/RBV (pegIFN).

    Time frame: 12 weeks after last dose of study drug

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The secondary endpoint was the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV.

    Time frame: 12 weeks after last dose of study drug

  2. Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment

    The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to \< LLN at the end of treatment.

    Time frame: Baseline (Day 1) and Week 12 (End of Treatment)

  3. Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate

    The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b treated with telaprevir and pegIFN/RBV.

    Time frame: 12 weeks after last dose of study drug

  4. Percentage of Participants With Virologic Failure During Treatment

    Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log10 IU/mL above the lowest value post baseline\] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).

    Time frame: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12

  5. Percentage of Participants With Virologic Relapse After Treatment

    Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (\<LLOQ) at the end of treatment were considered to have virologic relapse if they had confirmed HCV RNA ≥ LLOQ during the post-treatment period.

    Time frame: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-treatment)

07

Results

Posted Jan 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Started210209
Completed208207
Not completed22
Withdrew: Lost to follow-up22

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL. The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b infection treated with telaprevir and peginterferon/RBV (pegIFN).

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate99.5100.0
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV · Percentage of participants: 100 · 95% CI 98.2 to 100.095% CI was calculated using the Wilson score method for the single proportion because the point estimate was 100%..
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV · Percentage of participants: 99.5 · 95% CI 98.6 to 100.095% CI was calculated using the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The secondary endpoint was the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV.

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV99.5100
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV vs ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV · Difference in percentage of participants: 0.5 · 95% CI -0.5 to 1.495% CI was calculated using the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment

The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to \< LLN at the end of treatment.

Time frame:
Baseline (Day 1) and Week 12 (End of Treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment51.23.4
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV vs ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate

The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b treated with telaprevir and pegIFN/RBV.

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of particpants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate
percentage of particpantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate99.5100
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV · Percentage of participants: 100 · 95% CI 98.2 to 100.095% CI calculated using the Wilson score method for the single proportion; the lower confidence bound for the percentage of participants with sustained virologic response at 12 weeks after treatment must exceed 84% to achieve superiority.
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV · Percentage of participants: 99.5 · 95% CI 98.6 to 100.095% CI calculated using the normal approximation to the binomial distribution; the lower confidence bound for the percentage of participants with sustained virologic response at 12 weeks after treatment must exceed 84% to achieve superiority.
SecondaryPercentage of Participants With Virologic Failure During Treatment

Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log10 IU/mL above the lowest value post baseline\] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).

Time frame:
Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure During Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Rebound0.50
Failure to suppress00
SecondaryPercentage of Participants With Virologic Relapse After Treatment

Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (\<LLOQ) at the end of treatment were considered to have virologic relapse if they had confirmed HCV RNA ≥ LLOQ during the post-treatment period.

Time frame:
Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Relapse After Treatment
percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
Percentage of Participants With Virologic Relapse After Treatment00

Adverse events

Collected over AEs were collected from the time of study drug administration to 30 days after last dose of study drug (16 weeks); SAEs were also collected from the time that informed consent was obtained until the end of participation in the study (up to 65 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-450/r/ABT-267 and ABT-333, Plus RBV—4/210 (1.9%)133/210 (63.3%)
ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV—4/209 (1.9%)97/209 (46.4%)
Most frequent serious events
Most frequent serious events
EventABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
ARTHRITISMusculoskeletal and connective tissue disorders0/2101/209
MYALGIAMusculoskeletal and connective tissue disorders0/2101/209
INTRADUCTAL PROLIFERATIVE BREAST LESIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2101/209
UTERINE POLYPReproductive system and breast disorders0/2101/209
ATRIAL FIBRILLATIONCardiac disorders1/2100/209
CORONARY ARTERY DISEASECardiac disorders1/2100/209
NEPHROLITHIASISRenal and urinary disorders1/2100/209
EPIDIDYMITISReproductive system and breast disorders1/2100/209
Most frequent other events
Showing 10 of 12
Most frequent other events
EventABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
HEADACHENervous system disorders51/21049/209
FATIGUEGeneral disorders45/21049/209
PRURITUSSkin and subcutaneous tissue disorders25/21011/209
NAUSEAGastrointestinal disorders23/2109/209
ASTHENIAGeneral disorders22/21012/209
INSOMNIAPsychiatric disorders19/2107/209
COUGHRespiratory, thoracic and mediastinal disorders19/2105/209
ANAEMIABlood and lymphatic system disorders14/2101/209
DYSPEPSIAGastrointestinal disorders14/2109/209
DIARRHOEAGastrointestinal disorders9/21013/209

Baseline characteristics

All randomized participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)ABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBVTotal
Mean48.4 ± 11.9449.2 ± 12.0348.8 ± 11.98
Sex: Female, Male
Sex: Female, Male(Participants)ABT-450/r/ABT-267 and ABT-333, Plus RBVABT-450/r/ABT-267 and ABT-333, Plus Placebo RBVTotal
Female104123227
Male10686192
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. PubMed 24795200 ↗
  • Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int. 2018 Sep;38(9):1571-1575. doi: 10.1111/liv.13708. Epub 2018 Mar 14. PubMed 29377566 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2013 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2012
First posted
Jan 14, 2013
Start
Dec 2012
Primary completionActual
Dec 2013
CompletionActual
Aug 2014
Results first posted
Jan 6, 2015
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01767116
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Dec 2012
Primary completion
Dec 2013
Completion
Aug 2014
Results posted
Jan 6, 2015
Last update
Jul 12, 2021

Study contacts

Dan Cohen, MD
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion